Delving into the Latest Updates on Suzhou Ruiming New Drug Research & Development Co., Ltd. with Synapse

Overview

Tags

Cardiovascular Diseases

Endocrinology and Metabolic Disease

Eye Diseases

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Endocrinology and Metabolic Disease	1

Top 5 Drug Type	Count

Small molecule drug	1

Top 5 Target	Count

VEGF(Vascular endothelial growth factor)	1

Primary objective: To evaluate the local and systemic safety and tolerability of RA1115-B1 eye drops with different doses after single topical administration in healthy Chinese subjects. Secondary objective: To evaluate the systemic pharmacokinetic characteristics of RA1115-B1 eye drops with different doses after single topical administration in healthy Chinese subjects.

Start Date19 Aug 2022

Sponsor / Collaborator

Suzhou Ruiming New Drug Research & Development Co., Ltd.

100 Clinical Results associated with Suzhou Ruiming New Drug Research & Development Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Suzhou Ruiming New Drug Research & Development Co., Ltd.

Login to view more data

100 Deals associated with Suzhou Ruiming New Drug Research & Development Co., Ltd.

Login to view more data

100 Translational Medicine associated with Suzhou Ruiming New Drug Research & Development Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 04 Jun 2026

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

IND Application

1

Other

Login to view more data